الفهرس 
Review of Literature Fibrosis
Liver fibrosisOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
Background: BCG infection has been proven to induce
immune hepatic and pulmonary injury in rodent animal with
subsequent fibrosis development. Pirfenidone is an orally
available pyridone derivative that proven to have antiinflammatory
and anti-fibrotic effects in chemically and bile duct
ligation induced fibrosis.
Aim: The present study was undertaken to explore the potential
protective effect of pirfenidone (500mg/kg/day, via gastric
gavage) when coadministrated with BCG in an immunological
model of liver and lung fibrosis.
Methods: 18 female Balb/C mice were randomly divided into 3
groups (6 mice/each group); control group, BCG group and
BCG+ pirfenidone treated group. All the animals were sacrificed
on the 21th day of experiment. Liver function tests were
performed by measuring serum; aspartate aminotransferase
(AST), alanine aminotransferase (ALT). Hepatic and pulmonary
tissues were removed for measuring; hepatic and pulmonary
TNFα (tumor necrosis factor alpha), TGFβ (transforming growth
factor beta), hydroxyproline and for histopathological
examination.Results: Mice injected by BCG exhibited a significant increase in
the serum AST, ALT, hepatic and pulmonary TNFα, TGFβ and
hydroxyproline compared to control group. Concomitant
adminsitration of pirfenidone with BCG produced a significant
decrease in serum AST, ALT, hepatic and pulmonary TNFα,
TGFβ and hydroxyproline compared to BCG group. Along with
improvement of hepatic and pulmonary histopathological changes
that followed BCG in the form of restoration of normal hepatic
and pulmonary architecture, apparent decrease in inflammatory
cellular infiltration and significant decrease of hepatic and
pulmonary percentage area of collagen fibers deposition.
Conclusion: Pirfenidone has anti-inflammatory and antifibrotic
effects in an immune hepatic and pulmonary injury model of
induced by BCG in female Balb/C mice, and may represent a new
therapeutic strategy for liver and lung fibrosis that needs further
clinical evaluation.